Tolerance in the replacement of the benzhydrylic O atom in 4-[2- (diphenylmethoxy)ethyl]-1-benzylpiperidine derivatives by an N atom: Development of new-generation potent and selective N-analogue molecules for the dopamine transporter

Journal of Medicinal Chemistry

Volumn 41, Issue 17, 1998, Pages 3293-3297

  Dutta, Aloke K ^a   Xu, Cen ^b   Reith, Maarten E A ^b  

^a ORGANIX INC   (United States)

^b UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3BETA (4 FLUOROPHENYL) 2BETA TROPANECARBOXYLIC ACID METHYL ESTER; 4 [2 (DIPHENYLMETHOXY)ETHYL] 1 BENZYLPIPERIDINE DERIVATIVE; 4 [2 [(DIPHENYLMETHYL)AMINO]ETHYL] 1 [(4 FLUOROPHENYL)METHYL]PIPERIDINE; 4 [[[BIS(4 FLUOROPHENYL)METHYL]AMINO]ETHYL] 1 BENZYLPIPERIDINE; BENZHYDRYL DERIVATIVE; CITALOPRAM; COCAINE; DOPAMINE; DOPAMINE TRANSPORTER; NITROGEN; OXYGEN; PIPERIDINE DERIVATIVE; SEROTONIN TRANSPORTER; UNCLASSIFIED DRUG; VANOXERINE;

ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DRUG DEPENDENCE TREATMENT; DRUG POTENCY; DRUG SELECTIVITY; DRUG SYNTHESIS; HUMAN; HUMAN CELL; LIPOPHILICITY; MALE; NONHUMAN; RAT; STRUCTURE ACTIVITY RELATION;

ANIMALS; CARRIER PROTEINS; CELL LINE; CITALOPRAM; CLONING, MOLECULAR; COCAINE; CORPUS STRIATUM; DOPAMINE; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; DOPAMINE UPTAKE INHIBITORS; DRUG DESIGN; HUMANS; LIGANDS; MEMBRANE GLYCOPROTEINS; MEMBRANE TRANSPORT PROTEINS; MOLECULAR STRUCTURE; NERVE TISSUE PROTEINS; PIPERAZINES; PIPERIDINES; RATS; RATS, SPRAGUE-DAWLEY; RECOMBINANT PROTEINS; SEROTONIN; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; STRUCTURE-ACTIVITY RELATIONSHIP; TRANSFECTION;

EID: 0032514388     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm980066t     Document Type: Article

References (31)

1. Musto, D. F. Opium, Cocaine and Marijuana in American History. Sci. Am. 1991, 256, 40-47.
2. Reith, M. E. A.; Meisler, B. E.; Sershen, H.; Lajtha, A. Structural requirements for cocaine congeners to interact with dopamine and serotonin uptake sites in mouse brain and to induced stereotyped behavior. Biochem. Pharmacol. 1986, 35, 1123-1129.
3. Ritz, M. C.; Cone, E. J.; Kuhar, M. J. Cocaine inhibition of ligand binding at dopamine, norpinephrine and serotonin transporters: A structure-activity study. Life Sci. 1990, 46, 635-645.
4. Ritz, M. C.; Lamb, R. J.; Goldberg, R.; Kuhar, M. J. Cocaine receptors on dopamine transporters are related to self-adminstration of cocaine. Science 1987, 237, 1219-1223.
5. Giros, B.; Jaber, M.; Jones, S. R.; Wightman, R. M.; Caron, M. G. Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter. Nature 1996, 379, 606-612.
6. Carrol, F. I.; Lewin, A. H.; Kuhar, M. J. Dopamine transporter uptake blockers: Structure activity relationships. In Neurotransmitter Transporters: Structure and Function; Reith, M. E. A., Eds.; Human Press: Totowa, NJ, 1997; 263-295.
7. (a) Deutsch, H. M.; Shi, Q.; Gruszecka-Kowalik, E.; Schweri, M. M. Synthesis and pharmacology of potential cocaine antagonists. 2. Structure-activity relationship studies of aromatic ring substituted methylphenidate analogues. J. Med. Chem. 1996, 39, 1201-1209.
8. (b) Agoston, G. E.; Wu, J. H.; Izenwasser, S.; George, C.; Katz, J.; Kline, R. H.; Newman, A-H. Novel N-substituted 3α-[bis(4′-fluorophenyl)methoxy]tropane analogues: selective ligands for the dopamine transporter. J. Med. Chem. 1997, 40, 4329-4339.
9. Meltzer, P. C.; Liang, A. Y.; Blundell, P.; Gonzalez, M. D.; Chen, Z.; George, C.; Madras, B. K. 2-Carbomethoxy-3-aryl-8-oxabicyclo[3.2.1]octanes: Potent non-nitrogen inhibitors of monoamine transporters. J. Med. Chem. 1997, 40, 2661-2673.
10. Van der Zee, P.; Koger, H. S.; Gootjes, J.; Hespe, W. Aryl 1,4-dialk(en)ylpiperazines as selective and very potent inhibitors of dopamine uptake. Eur. J. Med. Chem. 1980, 15, 363-370.
11. 3H]GBR 12935 binding in vitro to rat striatal membranes: labeling of the dopamine uptake complex. J. Neurochem. 1987, 48, 1887-1896.
12. Anderson, P. H. The dopamine uptake inhibitor GBR 12909: selectivity and molecular mechanism of action. Eur. J. Pharmacol. 1989, 166, 493-504.
13. Matecka, D.; Lewis, D.; Rothman, R. B.; Dersch, C. M.; Wojnicki, F. H. E.; Glowa, J. R.; DeVries, C.; Pert, A.; Rice, K. C. Heteroaromatic analogues of 1-[2-(diphenylmethoxy)ethyl]- and 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazines (GBR 12935 and GBR 12909) as high-affinity dopamine reuptake inhibitors. J. Med. Chem. 1997, 40, 705-716.
14. Matecka, D.; Rothman, R. B.; Radesca, L.; De Costa, B.; Dersch, C. M.; Partilla, J. S.; Pert, A.; Glowa, J. R.; Wojnicki, F. H.; Rice, K. C. Development of novel, potent, and selective dopamine reuptake inhibitors through alteration of the piperazine ring of 1-[2-(diphenylmethoxy)ethyl]- and 1-[2-[Bis(4-fluorophenyl)-methoxy]ethyl]-4-(3-phenylpropyl)piperazines (GBR 12935 and GBR 12909). J. Med. Chem. 1996, 39, 4704-4716.
15. Dutta, A. K.; Meltzer, P. C.; Madras, B. K. Positional importance of the nitrogen atom in novel piperidine analogues of GBR 12909: Affinity and selectivity for the dopamine transporter. Med. Chem. Res. 1993, 3, 209-222.
16. Dutta, A. K.; Xu, C.; Reith, M. E. A. Structure-Activity Relationship Studies of Novel 4-[2-[Bis(4-fluorophenyl)methoxy]-ethyl]-1-(3-phenylpropyl)piperidine Analogues: Synthesis and Biological Evaluation at the Dopamine and Serotonin Transporter Sites. J. Med. Chem. 1996, 39, 749-756.
17. Dutta, A. K.; Coffey, L. L.; Reith, M. E. A. Highly selective, novel analogues of 4-[2-(diphenylmethoxy)ethyl]-1-benzylpiperidine for the dopamine transporter: Effect of different aromatic substitutions on their affinity and selectivity. J. Med. Chem. 1997, 40, 35-43.
18. Dutta, A. K.; Coffey, L. L.; Reith, M. E. A. Potent and selective ligands for the dopamine transporter (DAT): Structure-activity relationship studies of novel 4-[2-(diphenylmethoxy)ethyl]-1-(3-phenylpropyl)piperidine analogues. J. Med. Chem. 1998, 41, 699-705.
19. Carroll, F. I.; Gao, Y.; Abraham, P.; Lewin, A. H.; Lew, R.; Patel, A.; Boja, J. W.; Kuhar, M. J. Probes for the cocaine receptor: potentially irreversible ligands for the dopamine transporter. J. Med. Chem. 1992, 35, 1813-1817.
20. Fowler, J. S.; Volkow, N. D.; Wolf, A. P.; Dewey, S. L.; Schlyer, D. J.; Macgregor, R. R.; Hitzemann, R.; Logan, J.; Bendriem, B.; Gatley, S. J.; Christman, D. Mapping cocaine binding sites in human and baboon brain In Vivo. Synapse 1989, 4, 371-377.
21. Fischman, A. J.; Babich, J. W.; Elmaleh, D. R.; Barrow, S. A.; Meltzer, P.; Hanson, R. N.; Madras, B. K. SPECT imaging of dopamine transporter sites in normal and MPTP-treated rhesus monkeys. J. Nucl. Med. 1997, 38, 144-150.
22. Glowa, J. R.; Wojnicki, F. H. E.; Matecka, D.; Bacher, J. D.; Mansbach, R. S.; Balster, R. L.; Rice, K. C. Effects of dopamine reuptake inhibitors on food- and cocaine-maintained responding: I. Dependence on unit dose of cocaine. Exp. Clin. Psychopharmacol. 1995, 3, 219-231.
23. Glowa, J. R.; Wojnicki, F. H. E.; Matecka, D.; Rice, K. C.; Rothman, R. B. Effects of dopamine reuptake inhibitors on food- and cocaine-maintained responding: II. Comparisons with other drugs and repeated administrations. Exp. Clin. Psychopharmacol. 1995, 3, 232-239.
24. Rothman, R. B.; Mele, A.; Reid, A. A.; Akunne, H. C.; Greig, N.; Thurkauf, A.; de Costa, B. R.; Rice, K. C.; Pert, A. GBR 12909 antagonizes the ability of cocaine to elevate extracellular levels of dopamine. Pharmacol. Biochem. Behav. 1991, 40, 387-397.
25. Ho, G.-J.; Emerson, K. M.; Mathre, D. J.; Shuman, R. F.; Grabowski, E. J. Carbodiimide-mediated amide formation in a two-phase system. A high-yield and low-racemization procedure for peptide synthesis. J. Org. Chem. 1995, 60, 3569-3570.
26. Eshleman, A. J.; Neve, R. L.; Janowsky, A.; Neve, K. A. Characterization of a recombinant human dopamine transporter in multiple cell lines. J. Pharmacol. Exp. Ther. 1995, 274, 276-283.
27. Eshleman, A. J.; Stewart, E.; Evenson, A. K.; Mason, J. N.; Blakely, R. D.; Janowsky, A.; Neve, K. A. Metabolism of catecholamine by catechol-O-methyltransferase in cells expressing recombinant catecholamine transporters. J. Neurochem. 1997, 69, 1459-1466.
28. Ramamoorthy, S.; Bauman, A. L.; Moore, K. R.; Han, H.; Yang-Feng, T.; Chang, A. S.; Ganapathy, V.; Blakely, R. D. Anti-depressant- and cocaine-sensitive human serotonin transporter: molecular cloning, expression, and chromosomal localization. Proc. Natl Acad. Sci. U.S.A. 1993, 90, 2542-2546.
29. MacLogP Program, Version 2.0; BioByte Corp., Claremont, CA 91711.
30. Reith, M. E. A.; Xu, C.; Coffey, L. L. Binding domains for blockers and substrates on the cloned human dopamine transporter studied by protection against N-ethylmaleimide-induced reduction of 2beta-carboxy-3beta-(4-fluorophenyl)[3H]tropane ([3H]-WIN 35,428) binding. Biochem. Pharmacol. 1996, 52, 1435-1446.
31. Xu, C.; Coffey, L. L.; Reith, M. E. A. Translocation of dopamine and binding of 2 beta-carbomethoxy-3 beta-(4-fluorophenyl) tropane (WIN 35,428) measured under identical conditions in rat striatal synaptosomal preparations. Inhibition by various blockers. Biochem. Pharmacol. 1995, 49, 339-350.